Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
Prolonged vinorelbine exposure is correlated with improved antineoplastic effects, as evidenced by increased response rate in patients receiving continuous infusion. The administration of slow release pegylated liposomal vinorelbine formulation might mimic the pharmacokinetics of a continuous infusion, thus improving antitumor efficacy. But it is hard to prepare pegylated liposome vinorelbine using DSPE-PEG (an extensively used peglipid) because it could induce accelerated drug release. To resolve this problem, "post-insertion" technology was employed to prepare pegylated liposome vinorelbine formulations, which involved the incubation of vinorelbine-containing vesicles with DSPE-PEG micellar solutions. HPLC analysis revealed that after incubation at 60 degrees C for 60 min, approximately 100% DSPE-PEG could be inserted into the outer monolayer of the vesicles. Moreover, the grafting of peglipid did not induce the release of entrapped vinorelbine irrespective of intraliposomal anions. Drug release experiments indicated that "post-insertion" formulations were more able to retain entrapped drugs than "co-dissolving" formulations. The same phenomenon was observed when both series of formulations were injected in normal mice to compare pharmacokinetic profiles. In L1210 ascitic model, a "post-insertion" formulation with a PEG grafting density of approximately 0.5% exhibited the strongest antineoplastic effects, thus it was chosen to be further evaluated in S-180 and RM-1 models, in which the formulation was still more therapeutically active than conventional formulations. In conclusion, using "post-insertion" technology, the potential interaction between DSPE-PEG and vinorelbine could be prevented, thus making it possible to develop pegylated vinorelbine formulations.
Li
Chun Lei
CL
CSPC ZhongQi Pharmaceutical Technology, Shijiazhuang Co, Ltd, No 276, Shijiazhuang City, Hebei Province 050051, PR China. lcllib@hotmail.com
Cui
Jing Xia
JX
Wang
Cai Xia
CX
Zhang
Lan
L
Li
Yan Hui
YH
Zhang
Li
L
Xiu
Xian
X
Li
Yong Feng
YF
Wei
Na
N
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004339:Drug Compounding / Q000379:methods*; D006801:Humans; D008081:Liposomes / Q000138:chemical synthesis*; D051379:Mice; D008815:Mice, Inbred Strains; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000077235:Vinorelbine; D023041:Xenograft Model Antitumor Assays
D000972:Antineoplastic Agents, Phytogenic; D008081:Liposomes; D011092:Polyethylene Glycols; D014747:Vinblastine; D000077235:Vinorelbine